RxDoctor Payments Data

John Eatman, MD

Neurology · North Kansas City, MONPI 1942596523

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $52,372 of the $83,853 with a category attached, or 62.5%. 43 manufacturers reported payments, led by AstraZeneca at 46.0% of the total. Reporting peaked in 2019 at $22,932 and has fallen 82.6% since, to $3,989 in 2025. Among neurology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$83,853in general payments, 2019–2025

Across 477 payments — averaging $175.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$39K
  • Alnylam Pharmaceuticals Inc.$34K
  • Amgen$3K
  • AbbVie$2K
  • Argenx US, Inc.$1K
  • Akcea Therapeutics, Inc.$1K
  • plus $4K from 37 others

What the payments were for

  • Consulting fees$13,56816%
  • Speaking & faculty fees$52,37262%
  • Travel & lodging$9,51211%
  • Food & beverage$8,33710%
  • Education$640%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$83,853 in reported general payments places this provider in the 90th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$101,850
Medicare patients
291
Services billed
2,355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab13$724,523
Gamunex-CImmune Globul G/Gly/Iga Avg 46115$347,466
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5018$147,683
Nurtec OdtRimegepant Sulfate18$31,998
Dimethyl Fumarate14$28,256
Emgality PenGalcanezumab-Gnlm13$8,546
Rivastigmine27$7,863
Pyridostigmine Bromide81$5,571
Gabapentin224$4,129
Pregabalin216$3,955
Carbidopa-LevodopaCarbidopa/Levodopa178$3,396
Duloxetine Hcl109$2,408
Donepezil Hcl224$2,020
Baclofen73$1,550
Memantine Hcl65$1,433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris$38,546$724,52313 claims
Grifols USA, LLCGamunex-C$14$347,466115 claims
PfizerNurtec Odt$397$31,99818 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$322$5,57181 claims
Upsher-smith Laboratories LLCTopiramate$69$1,07370 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 381 neurology providers in Missouri.

Other neurology in North Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →